Chest CT for Prostate Cancer: ADT Guidelines
- For men undergoing androgen deprivation therapy (ADT) for prostate cancer, a groundbreaking study reveals a new way to monitor for potential heart problems.
- Prostate cancer treatment often involves ADT, which lowers testosterone levels to slow cancer growth.
- The research, published in the European Journal of Radiology, followed 180 prostate cancer patients (with a median age of 70) undergoing ADT.
Early Heart Risk Detection for Prostate Cancer Patients: A New Imaging Approach
Table of Contents
Published August 20, 2025
For men undergoing androgen deprivation therapy (ADT) for prostate cancer, a groundbreaking study reveals a new way to monitor for potential heart problems. Researchers have found that assessing the myocardial extracellular volume (ECV) using chest contrast-enhanced computed tomography (CECT) can identify cardiotoxicity - damage to the heart – and predict major adverse cardiovascular events (MACE) earlier than traditional methods.
Prostate cancer treatment often involves ADT, which lowers testosterone levels to slow cancer growth. While effective, ADT can unluckily have side effects on the cardiovascular system. Identifying these risks early is crucial for improving patient outcomes.
How the Study Uncovered the Link
The research, published in the European Journal of Radiology, followed 180 prostate cancer patients (with a median age of 70) undergoing ADT. Researchers used CECT scans to measure ECV – the volume of space between heart muscle cells – at the start of treatment and then at three, six, nine, and twelve months.
The results were critically important: a notable increase in myocardial ECV was observed just three months after starting ADT (a 27.93% increase compared to a baseline of 23.45%). While the left ventricular ejection fraction (LVEF),a common measure of heart function,didn’t change significantly at three months,it did show a slight decrease after a year.
Importantly, 24% of the study participants (44 patients) experienced a MACE during the study period. Those who developed MACE consistently had higher ECV levels at all time points compared to those who didn’t. After one year of ADT, the MACE group had an average ECV of 38.80%, while the non-MACE group had an ECV of 32.06%.
Why ECV Matters: Detecting Problems Before They Escalate
The study’s lead author, Xinyu Zhang, M.D., and colleagues, emphasized that the increase in ECV occurred before any significant changes were seen in LVEF. This suggests that ECV is a more sensitive early indicator of ADT-induced cardiotoxicity. Patients with higher ECV levels at three months had a 2.695-fold increased risk of MACE, rising to 4.450-fold at nine months.
The researchers suggest that routine chest CECT scans to measure ECV could become a standard practice for prostate cancer patients starting ADT, pending further confirmation from larger, prospective studies.
Limitations and Future Directions
The study authors acknowledge certain limitations, including its retrospective design and the fact that it focused on a single center. They also noted a lack of comparison between different types of castrating drugs and the absence of cardiac biopsies for patients who experienced MACE. Furthermore, patients who died from non-cardiovascular causes were excluded from the analysis.
Despite these limitations, the findings provide compelling evidence for the value of ECV monitoring. Future research will focus on confirming these results in larger, more diverse populations and exploring the potential benefits of using ECV to guide treatment decisions.